Mercer Global Advisors
AKBA icon

Mercer Global Advisors’s Akebia Therapeutics AKBA Stock Holding History

Mercer Global Advisors’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$16.3K Buy
+11,692
New +$16.1K ﹤0.01% 3190
2024
Q4 		– Sell
-38,721
Closed -$49.6K – 2120
2024
Q3 		$49.6K Buy
38,721
+7,500
+24% +$10K ﹤0.01% 1916
2024
Q2 		$31.8K Buy
31,221
+9,037
+41% +$11.2K ﹤0.01% 1931
2024
Q1 		$41K Buy
22,184
+2,498
+13% +$3.99K ﹤0.01% 1899
2023
Q4 		$24K Sell
19,686
-274
-1% -$279 ﹤0.01% 1985
2023
Q3 		$23K Hold
19,960
– – ﹤0.01% 1921
2023
Q2 		$18K Buy
+19,960
New +$19.3K ﹤0.01% 1897

Other funds holding AKBA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Mercer Global Advisors's AKBA Position: Q1 2026 in Review

Mercer Global Advisors opened a new position in Akebia Therapeutics (AKBA) in Q1 2026: 11,692 shares worth $16.3K. The stake represents ﹤0.01% of the portfolio and ranks #3190 among its holdings. This is a return to the name: Mercer Global Advisors previously reported a position in AKBA as recently as Q3 2024.

Mercer Global Advisors first reported a position in AKBA in Q2 2023 and has held it in 7 quarters since. The position peaked at $49.6K in Q3 2024. 171 funds tracked by Wall St. Rank hold AKBA as of Q1 2026.

  • Mercer Global Advisors held 11,692 shares of Akebia Therapeutics worth $16.3K as of Q1 2026.
  • Akebia Therapeutics was a new Mercer Global Advisors position in Q1 2026.
  • Akebia Therapeutics made up ﹤0.01% of Mercer Global Advisors's portfolio in Q1 2026, its #3190 holding.
  • Mercer Global Advisors first reported a position in Akebia Therapeutics in Q2 2023 and has held it in 7 quarters since.
  • Mercer Global Advisors's Akebia Therapeutics position peaked at $49.6K in Q3 2024.
  • 171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2026.

Based on Mercer Global Advisors's 13F filing for Q1 2026, filed 15 May 2026.